Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting

On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) concluded its second-quarter 2026 earnings call, showcasing its focus on the oral ITK inhibitor Soquelitinib. This single drug spans multiple diseases, including a rare blood cancer and asthma. The company's data reveals both promising and concerning aspects. In atopic dermatitis, 75% of patients in the highest dose cohort achieved EASI-75 after 8 weeks of 200 mg dosing, compared to 20% on placebo.

A quarter reached EASI-90, and a third achieved clear skin, outcomes not matched by placebo patients. Importantly, the benefits persisted after dosing stopped without rebound effects. Corvus has $215 million in cash, up from $56.8 million a year prior, thanks to a successful Q1 offering. However, R&D costs surged to $16 million, leading to a net loss almost double the previous year.

The company's future remains uncertain, with its most advanced program in a 2027 futility check for a lymphoma trial. Despite strong interest from hedge funds and a potential ally in Angel Pharmaceuticals in China, short sellers remain active, leading to a mixed market sentiment. While Corvus has a well-funded runway and a promising atopic dermatitis dataset, the stock's potential hinges on further data from ongoing trials.